直肠癌的术前辅助治疗研究

新辅助放化疗已经成为Ⅱ／Ⅲ期直肠癌的标准治疗模式，与术后放化疗相比提高了肿瘤的局部控制率，增加患者的保肛率，减轻了患者的毒性反应，提高生存率及生活质量。随着更多有效的药物及新配伍方案的引入，对直肠癌患者采取个体化的术前放化疗，将使直肠癌的治疗效果得到进一步提高。本文就直肠癌术前放化疗的现状和进展进行综述。

Study on preoperative adjuvant therapy for rectal cancer

Neoadjuvant ehemoradiotherapy has been applied as standard treatment for stage Ⅱ and Ⅲ rectal cancer, which has better local control rate, sphincter preservation rate, survival rate, quality of life and lower toxicity comparing with postoperative ehemoradiotherapy. With more and more application of chemotherapeutic agents and new compatibility regimen, individualized preoperative chemoradiotherapy will further improve therapeutic efficacy of rectal cancer. This article reviewed current status and development of preoperative radioehemotherapy for rectal cancer.